PE20081791A1 - Dos derivados ciclicos de oxomorfolina - Google Patents

Dos derivados ciclicos de oxomorfolina

Info

Publication number
PE20081791A1
PE20081791A1 PE2008000381A PE2008000381A PE20081791A1 PE 20081791 A1 PE20081791 A1 PE 20081791A1 PE 2008000381 A PE2008000381 A PE 2008000381A PE 2008000381 A PE2008000381 A PE 2008000381A PE 20081791 A1 PE20081791 A1 PE 20081791A1
Authority
PE
Peru
Prior art keywords
oxazin
oxomorpholin
trifluorophenyl
ona
tetrahydro
Prior art date
Application number
PE2008000381A
Other languages
English (en)
Inventor
Teiji Kimura
Noritaka Kitazawa
Toshihiko Kaneko
Takehiko Miyagawa
Koki Kawano
Mamoru Takaishi
Takeo Sasaki
Eriko Doi
Koichi Ito
Nobuaki Sato
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39716667&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081791(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20081791A1 publication Critical patent/PE20081791A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE OXOMORFOLINA DE FORMULA I, DONDE R1 ES ALQUILO C1-C3; R2 ES H, ALQUILO C1-C3 O R1 Y R2 JUNTO AL CARBONO AL QUE ESTAN UNIDO SON CICLOALQUILO C3-C6; Ar ES FENILO SUSTITUIDO O NO; X ES METILENO SUSTITUIDO O NO; m Y n SON 0-2. SON SELECCIONADOS: (Z)(1R, 6R, 9aR)-3-[3-METOXI-4-(4-METILIMIDAZOL-1-IL)BENCILIDEN]-1-METIL-6-(3,4,5-TRIFLUOROFENIL)TETRAHIDRO-[1,4]OXAZIN[3,4-c][1,4]-OXAZIN-4-ONA; (6R,9aR)-3-[1-[3-METOXI-4-(4-METIL-1H-IMIDAZOL-2-IL)FENIL-(Z)-METILIDEN]-1,1-DIMETIL-6-(3,4,5-TRIFLUOROFENIL)TETRAHIDRO[1,4[OXAZIN[3,4-c][1,4]OXAZIN-4-ONA; ENTRE OTROS. DICHOS COMPUESTOS SON DE UTILIDAD EN EL TRATAMIENTO DE ENFERMEDADES ATRIBUIBLES A AMILOIDE BETA, TALES COMO ALZHEIMER, DEMENCIA SENIL, SINDROME DE DOWN O AMILOIDOSIS
PE2008000381A 2007-02-28 2008-02-26 Dos derivados ciclicos de oxomorfolina PE20081791A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89199707P 2007-02-28 2007-02-28
JP2007049085 2007-02-28

Publications (1)

Publication Number Publication Date
PE20081791A1 true PE20081791A1 (es) 2009-02-07

Family

ID=39716667

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000381A PE20081791A1 (es) 2007-02-28 2008-02-26 Dos derivados ciclicos de oxomorfolina

Country Status (11)

Country Link
US (2) US20080207900A1 (es)
EP (1) EP2125829B1 (es)
JP (1) JP5244096B2 (es)
KR (1) KR20090116704A (es)
CN (1) CN101622258B (es)
AU (1) AU2008221906C1 (es)
CA (1) CA2678100A1 (es)
CL (1) CL2008000582A1 (es)
PE (1) PE20081791A1 (es)
TW (1) TW200848054A (es)
WO (1) WO2008108378A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100966749B1 (ko) * 2004-05-26 2010-06-30 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
AR068121A1 (es) * 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
WO2009067493A2 (en) * 2007-11-19 2009-05-28 Envivo Pharmaceuticals, Inc. 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
KR20100135711A (ko) 2007-12-20 2010-12-27 엔비보 파마슈티칼즈, 인코퍼레이티드 사중치환된 벤젠
BRPI1007883A2 (pt) 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd sal, e, cristal.
KR20110122746A (ko) 2009-02-26 2011-11-10 에자이 알앤드디 매니지먼트 가부시키가이샤 질소를 함유하는 융합된 헤테로사이클릭 화합물 및 β 아밀로이드 생산 저해제로서의 용도
TW201111361A (en) * 2009-06-24 2011-04-01 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
JP2012530758A (ja) * 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
EP2547685A1 (en) 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
MX2012010657A (es) 2010-03-15 2013-02-07 Amgen Inc Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EA033423B1 (ru) 2015-02-03 2019-10-31 Pfizer Циклопропанбензофуранилпиридопиразиндионы
JPWO2019098256A1 (ja) * 2017-11-16 2020-12-03 株式会社幹細胞＆デバイス研究所 デバイス

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1101156A (en) * 1965-09-22 1968-01-31 Hickson & Welch Ltd Triazole derivatives and their use as optical whitening agents
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
FR2314731A1 (fr) 1975-06-19 1977-01-14 Nelson Res & Dev Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US4508718A (en) 1984-01-16 1985-04-02 Warner-Lambert Company Cardiotonic and antihypertensive oxadiazinone compounds
DE3689506D1 (de) 1985-10-09 1994-02-17 Shell Int Research Neue Acrylsäureamide.
US4783463A (en) 1985-10-23 1988-11-08 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
FI91754C (fi) 1986-12-02 1994-08-10 Tanabe Seiyaku Co Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi
FI902321A0 (fi) 1989-05-19 1990-05-09 Eisai Co Ltd Butensyraderivat.
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
ATE153655T1 (de) * 1990-02-08 1997-06-15 Eisai Co Ltd Benzensulfonamidderivat
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
JPH10510512A (ja) 1994-10-04 1998-10-13 藤沢薬品工業株式会社 尿素誘導体とａｃａｔ阻害剤としての用途
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
CZ251896A3 (en) * 1995-09-12 1997-04-16 Hoffmann Ka Roche Ag F Cephalosporin derivatives
WO1997014417A1 (en) 1995-10-19 1997-04-24 Merck & Co., Inc. Fibrinogen receptor antagonists
JP3418405B2 (ja) 1996-05-10 2003-06-23 アイコス コーポレイション カルボリン誘導体
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
WO1998024785A1 (en) 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
CA2281875A1 (en) 1997-03-31 1998-10-08 Takeda Chemical Industries, Ltd. Azole compounds, their production and their use
TW379224B (en) 1997-12-02 2000-01-11 Fujisawa Pharmaceutical Co Urea derivatives
WO1999033846A2 (en) 1997-12-31 1999-07-08 The University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6235728B1 (en) * 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
WO2000051981A1 (en) * 1999-03-04 2000-09-08 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
US20040087798A1 (en) * 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US20010051642A1 (en) * 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
EP1349839B8 (en) * 2000-12-04 2005-06-22 F. Hoffmann-La Roche Ag Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
WO2003022273A1 (en) 2001-09-13 2003-03-20 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
HUP0401492A3 (en) 2001-09-14 2008-05-28 Novo Nordisk As Novel ligands for the hisb10 zn2+ sites of r-state insulin hexa
PL373484A1 (en) 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
ATE430727T1 (de) * 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
WO2003062206A2 (en) 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
AU2003225668A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
ES2355472T3 (es) * 2002-05-22 2011-03-28 Amgen Inc. Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor.
SI1511710T1 (sl) 2002-05-31 2014-04-30 Proteotech, Inc. Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
WO2004002478A1 (en) 2002-06-27 2004-01-08 Elan Pharmaceuticals, Inc. Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
MXPA05000053A (es) 2002-07-12 2005-04-08 Aventis Pharma Gmbh Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos.
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
WO2004071447A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as therapeutic agents
KR20050111629A (ko) 2003-04-01 2005-11-25 플러스 케미칼스 비.브이. 무정형 심바스타틴 칼슘 및 그의 제조방법
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
US8362017B2 (en) * 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
WO2005063754A1 (en) 2003-12-22 2005-07-14 Pfizer Limited Triazole derivatives as vasopressin antagonists
WO2005072731A1 (en) 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
JP4625838B2 (ja) 2004-03-09 2011-02-02 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラーゼ阻害薬
KR100966749B1 (ko) * 2004-05-26 2010-06-30 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
WO2006018662A2 (en) 2004-08-16 2006-02-23 Prosidion Limited Aryl urea derivatives for treating obesity
CN100577657C (zh) 2004-10-26 2010-01-06 卫材R&D管理有限公司 肉桂酰胺化合物的无定形物
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
EP1953151A4 (en) 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
AU2006316005A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
MY144960A (en) * 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
GEP20115139B (en) 2006-03-09 2011-01-10 Eisai R&D Man Co Ltd Polycyclic cinnamide derivative
SA07280403B1 (ar) * 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
KR20100017573A (ko) 2007-05-07 2010-02-16 쉐링 코포레이션 감마 세크레타제 조정인자
WO2008138753A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ASSOCIATED STATES
MX2010001506A (es) 2007-08-06 2010-03-10 Schering Corp Moduladores de gamma secretasa.

Also Published As

Publication number Publication date
AU2008221906B2 (en) 2012-04-12
JP5244096B2 (ja) 2013-07-24
KR20090116704A (ko) 2009-11-11
JP2010520152A (ja) 2010-06-10
EP2125829A2 (en) 2009-12-02
US20100113773A1 (en) 2010-05-06
US8008293B2 (en) 2011-08-30
AU2008221906A1 (en) 2008-09-12
AU2008221906C1 (en) 2012-12-13
CA2678100A1 (en) 2008-09-12
US20080207900A1 (en) 2008-08-28
WO2008108378A3 (en) 2008-12-04
WO2008108378A2 (en) 2008-09-12
CL2008000582A1 (es) 2008-06-27
TW200848054A (en) 2008-12-16
CN101622258B (zh) 2012-06-13
CN101622258A (zh) 2010-01-06
EP2125829B1 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
PE20081791A1 (es) Dos derivados ciclicos de oxomorfolina
BRPI0518169A (pt) tiazolil-dihidro-indazóis
DOP2009000232A (es) Metanoisoindoles y dionas de éstos como agentes anti-psicóticos.
MY152386A (en) Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones
AR082154A1 (es) DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA COMO MODULADORES DE IRAK4
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
PE20110296A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de orexina
SG195289A1 (en) Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
AR091781A1 (es) Antagonistas del receptor de 5-ht3
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
NZ592642A (en) Tricyclic oxazolidinone antibiotic compounds
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
CL2010001162A1 (es) Compuestos derivados de octahidropirrolo[3,4-c]pirrol disustituidos, moduladores de orexina; composicion farmaceutica que comprende a dichos compuestos; utiles en trastornos del ciclo sueño-vigilia, trastornos metabolicos, trastornos neurologicos, entre otros
NZ631187A (en) Tricyclic quinoline and quinoxaline derivatives
PE20110777A1 (es) Nuevas lactamas como inhibidores de beta secretasa
NZ590297A (en) 2-Alkylamino-7,8-dihydropteridin-6(5H)-one and 2-alkylamino-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one derivatives
AR078437A1 (es) Derivados de imidazopiridina, procesos de obtencion y composiciones farmaceuticas
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
PE20120054A1 (es) COMPUESTOS DERIVADOS DE 4,8-DIHIDRO-4,7-METANO-7H-PIRAZOLO[3,4-e][1,3]DIAZEPINA-6(5H)-ONA CON ACTIVIDAD ANTIBACTERIANA
UY32046A (es) Derivados de 2-alquil-6-cicloamino-3-(piridin-4-il)imidazoz[1,2-b]-piridazina, su preparación y su aplicación en terapéutica
EA201171393A1 (ru) 7-([1,2,4]ТРИАЗОЛО[1,5α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН И ЕГО ПРИМЕНЕНИЕ
ES2587745T3 (es) Derivados de imidazo[2,1]tiazol-3-ona útiles como agentes de diagnóstico para la enfermedad de Alzheimer
CO6341621A2 (es) Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1
WO2008110690A3 (fr) Nouveaux derives indoliques, leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens

Legal Events

Date Code Title Description
FA Abandonment or withdrawal